1Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Researchers are improving thrombolytic agents like streptokinase and urokinase by modifying their structure to enhance potency and reduce antigenicity. These engineered therapies aim for better fibrin-selectivity and therapeutic potential in treating blood clots.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science: